

CONTENTS

| | |
|--|-----------|
| NOTE TO THE READER | 1 |
| LIST OF PARTICIPANTS | 3 |
| PREAMBLE | 9 |
| A. GENERAL PRINCIPLES AND PROCEDURES | 9 |
| 1. Background..... | 9 |
| 2. Objective and scope..... | 10 |
| 3. Selection of agents for review | 11 |
| 4. Data for the <i>Monographs</i> | 11 |
| 5. Meeting participants..... | 12 |
| 6. Working procedures..... | 13 |
| B. SCIENTIFIC REVIEW AND EVALUATION..... | 14 |
| 1. Exposure data | 15 |
| 2. Studies of cancer in humans | 16 |
| 3. Studies of cancer in experimental animals..... | 20 |
| 4. Mechanistic and other relevant data..... | 23 |
| 5. Summary..... | 26 |
| 6. Evaluation and rationale..... | 27 |
| References | 31 |
| GENERAL REMARKS | 33 |
| BUSULFAN | 39 |
| 1. Exposure Data | 39 |
| 1.1 Identification of the agent..... | 39 |
| 1.2 Use of the agent | 39 |
| 2. Cancer in Humans..... | 40 |
| 3. Cancer in Experimental Animals | 41 |
| 4. Other Relevant Data | 41 |
| 4.1 Absorption, distribution, metabolism, and excretion..... | 41 |
| 4.2 Genotoxic effects | 42 |
| 4.3 Mechanisms of carcinogenesis | 43 |
| 4.4 Synthesis..... | 43 |
| 5. Evaluation | 43 |
| References | 43 |

| | |
|---|-----------|
| CHLORAMBUCIL | 47 |
| 1. Exposure Data | 47 |
| 1.1 Identification of the agent..... | 47 |
| 1.2 Use of the agent | 47 |
| 2. Cancer in Humans..... | 48 |
| 2.1 Cancers following treatment for various diseases..... | 48 |
| 2.2 Cancers following treatment for chronic lymphocytic leukaemia | 49 |
| 3. Cancer in Experimental Animals | 49 |
| 4. Other Relevant Data | 52 |
| 4.1 Absorption, distribution, metabolism, and excretion..... | 52 |
| 4.2 Genotoxic effects | 52 |
| 4.3 Synthesis..... | 53 |
| 5. Evaluation | 53 |
| References | 53 |
| METHYL-CCNU | 57 |
| 1. Exposure Data | 57 |
| 1.1 Identification of the agent..... | 57 |
| 1.2 Use of the agent | 57 |
| 2. Cancer in Humans..... | 58 |
| 3. Cancer in Experimental Animals | 58 |
| 4. Other Relevant Data | 58 |
| 4.1 Absorption, distribution, metabolism, and excretion..... | 58 |
| 4.2 Genotoxic effects | 59 |
| 4.3 Mechanisms of carcinogenesis | 60 |
| 4.4 Synthesis..... | 60 |
| 5. Evaluation | 60 |
| References | 60 |
| CYCLOPHOSPHAMIDE | 63 |
| 1. Exposure Data | 63 |
| 1.1 Identification of the agent..... | 63 |
| 1.2 Use of the agent | 63 |
| 2. Cancer in Humans..... | 66 |
| 2.1 Synthesis..... | 67 |
| 3. Cancer in Experimental Animals | 67 |
| 4. Other Relevant Data | 73 |
| 4.1 Absorption, distribution, metabolism, and excretion..... | 73 |
| 4.2 Genetic and related effects..... | 73 |
| 4.3 Mechanisms of carcinogenesis | 77 |
| 4.4 Synthesis..... | 82 |
| 5. Evaluation | 82 |
| References | 83 |
| ETOPOSIDE IN COMBINATION WITH CISPLATIN AND BLEOMYCIN | 91 |
| 1. Exposure Data | 91 |
| 1.1 Identification of the agent..... | 91 |
| 1.2 Use of the agents | 92 |

| | |
|--|------------|
| 2. Cancer in Humans..... | 95 |
| 3. Cancer in Experimental Animals | 99 |
| 4. Other Relevant Data | 99 |
| 4.1 Absorption, distribution, metabolism, and excretion..... | 99 |
| 4.2 Mechanisms of carcinogenesis | 99 |
| 4.3 Synthesis..... | 101 |
| 5. Evaluation | 101 |
| References | 102 |
| MELPHALAN | 107 |
| 1. Exposure Data | 107 |
| 1.1 Identification of the agent..... | 107 |
| 1.2 Use of the agent | 107 |
| 2. Cancer in Humans..... | 108 |
| 3. Cancer in Experimental Animals | 109 |
| 4. Other Relevant Data | 109 |
| 4.1 Absorption, distribution, metabolism, and excretion..... | 109 |
| 4.2 Mechanisms of carcinogenesis | 112 |
| 4.3 Synthesis..... | 113 |
| 5. Evaluation | 113 |
| References | 113 |
| MOPP | 119 |
| 1. Exposure Data | 119 |
| 1.1 Identification of the agent..... | 119 |
| 1.2 Use of the combination..... | 121 |
| 2. Cancer in Humans..... | 121 |
| 2.1 Acute myeloid leukaemia..... | 121 |
| 2.2 Cancer of the lung..... | 122 |
| 2.3 Other sites | 122 |
| 3. Cancer in Experimental Animals | 123 |
| 4. Other Relevant Data | 123 |
| 4.1 Synthesis..... | 126 |
| 5. Evaluation | 126 |
| References | 126 |
| TAMOXIFEN | 131 |
| 1. Exposure Data | 131 |
| 1.1 Identification of the agent..... | 131 |
| 1.2 Use of the agent | 132 |
| 2. Cancer in Humans..... | 133 |
| 2.1 Cancer of the endometrium..... | 133 |
| 2.2 Contralateral breast cancer..... | 135 |
| 2.3 Chemoprevention of cancer of the breast | 135 |
| 2.4 Gastrointestinal cancers | 136 |
| 2.5 Cancer of the ovary..... | 136 |
| 2.6 Synthesis..... | 136 |

| | |
|--|------------|
| 3. Cancer in Experimental Animals | 137 |
| 3.1 Oral administration..... | 137 |
| 3.2 Subcutaneous administration | 137 |
| 3.3 Perinatal administration | 137 |
| 3.4 Administration with known carcinogens..... | 148 |
| 3.5 Synthesis..... | 148 |
| 4. Other Relevant Data | 148 |
| 4.1 Absorption, distribution, metabolism, and excretion..... | 148 |
| 4.2 Genetic and related effects..... | 151 |
| 4.3 Synthesis..... | 155 |
| 5. Evaluation | 155 |
| References | 155 |
| THIOTEPA..... | 163 |
| 1. Exposure Data | 163 |
| 1.1 Identification of the agent..... | 163 |
| 1.2 Use of the agent | 163 |
| 2. Cancer in Humans..... | 164 |
| 3. Cancer in Experimental Animals | 164 |
| 4. Other Relevant Data | 166 |
| 4.1 Absorption, distribution, metabolism, and excretion..... | 166 |
| 4.2 Genotoxic effects | 166 |
| 4.3 Synthesis..... | 168 |
| 5. Evaluation | 168 |
| References | 168 |
| TREOSULFAN..... | 171 |
| 1. Exposure Data | 171 |
| 1.1 Identification of the agent..... | 171 |
| 1.2 Use of the agent | 171 |
| 2. Cancer in Humans..... | 172 |
| 3. Cancer in Experimental Animals | 172 |
| 4. Other Relevant Data | 172 |
| 4.1 Absorption, distribution, metabolism, and excretion..... | 172 |
| 4.2 Genotoxic effects | 172 |
| 4.3 Synthesis..... | 173 |
| 5. Evaluation | 173 |
| References | 173 |
| DIETHYLSTILBESTROL..... | 175 |
| 1. Exposure Data | 175 |
| 1.1 Identification of the agent..... | 175 |
| 1.2 Use of the agent | 175 |
| 2. Cancer in Humans..... | 177 |
| 2.1 Women exposed to diethylstilbestrol during pregnancy | 177 |
| 2.2 Women exposed <i>in utero</i> | 180 |

| | | |
|---|--|------------|
| 2.3 | Men exposed to diethylstilbestrol..... | 183 |
| 2.4 | Offspring (third generation) of women who were exposed to diethylstilbestrol <i>in utero</i> | 185 |
| 2.5 | Synthesis..... | 186 |
| 3. | Cancer in Experimental Animals | 186 |
| 3.1 | Oral administration..... | 186 |
| 3.2 | Subcutaneous and/or intramuscular administration | 186 |
| 3.3 | Subcutaneous implantation | 190 |
| 3.4 | Perinatal exposure..... | 190 |
| 3.5 | Synthesis..... | 192 |
| 4. | Other Relevant Data | 198 |
| 4.1 | Absorption, distribution, metabolism, and excretion..... | 198 |
| 4.2 | Genetic and related effects..... | 199 |
| 4.3 | Synthesis..... | 206 |
| 5. | Evaluation | 206 |
| | References | 207 |
| ESTROGEN-ONLY MENOPAUSAL THERAPY..... | | 219 |
| 1. | Exposure Data | 219 |
| 1.1 | Identification of the agents..... | 219 |
| 1.2 | Use of the agents | 223 |
| 2. | Cancer in Humans..... | 227 |
| 2.1 | Cancer of the breast..... | 227 |
| 2.2 | Cancer of the endometrium..... | 228 |
| 2.3 | Cancer of the colorectum..... | 229 |
| 2.4 | Cancer of the ovary..... | 229 |
| 2.5 | Cancer of the urinary bladder..... | 230 |
| 2.6 | Cancer of the pancreas..... | 231 |
| 2.7 | Exogenous estrogen use and melanoma risk..... | 231 |
| 2.8 | Cancer of the cervix | 231 |
| 2.9 | Cancer of the thyroid..... | 231 |
| 2.10 | Synthesis..... | 231 |
| 3. | Cancer in Experimental Animals | 232 |
| 3.1 | Summary of the previous <i>IARC Monograph</i> | 232 |
| 3.2 | Studies published since the previous <i>IARC Monograph</i> | 234 |
| 3.3 | Synthesis..... | 237 |
| 4. | Other Relevant Data | 237 |
| 4.1 | Absorption, distribution, metabolism, and excretion..... | 237 |
| 4.2 | Genetic and related effects..... | 238 |
| 4.3 | Synthesis..... | 241 |
| 5. | Evaluation | 241 |
| | References | 241 |
| COMBINED ESTROGEN–PROGESTOGEN MENOPAUSAL THERAPY | | 249 |
| 1. | Exposure Data | 249 |
| 1.1 | Identification of the agents..... | 249 |
| 1.2 | Use of the agents | 255 |

| | |
|--|-----|
| 2. Cancer in Humans..... | 256 |
| 2.1 Cancer of the breast..... | 256 |
| 2.2 Cancer of the endometrium..... | 263 |
| 2.3 Cancer of the colorectum..... | 264 |
| 2.4 Cancer of the ovary..... | 265 |
| 2.5 Cancer of the skin..... | 266 |
| 2.6 Cancer of the thyroid..... | 267 |
| 2.7 Lymphomas and leukaemias..... | 267 |
| 2.8 Cancers of the central nervous system..... | 267 |
| 2.9 Cancer of the urinary tract..... | 267 |
| 2.10 Cancer of the lung..... | 268 |
| 2.11 Cancer of the pancreas..... | 268 |
| 2.12 Cancer of the stomach..... | 269 |
| 2.13 Cancer of the cervix..... | 269 |
| 2.14 Cancer of the liver..... | 269 |
| 2.15 Synthesis..... | 269 |
| 3. Cancer in Experimental Animals..... | 269 |
| 3.1 Summary of the previous <i>IARC Monograph</i> | 269 |
| 3.2 Studies published since the previous <i>IARC Monograph</i> | 270 |
| 4. Other Relevant Data..... | 274 |
| 4.1 Absorption, distribution, metabolism, and excretion..... | 274 |
| 4.2 Genetic and related effects..... | 274 |
| 4.3 Synthesis..... | 277 |
| 5. Evaluation..... | 277 |
| References..... | 278 |

COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES 283

| | |
|---|-----|
| 1. Exposure Data..... | 283 |
| 1.1 Identification of the agents..... | 283 |
| 1.2 Use of the agents..... | 283 |
| 2. Cancer in Humans..... | 286 |
| 2.1 Cancer of the breast..... | 286 |
| 2.2 Cancer of the endometrium..... | 291 |
| 2.3 Cancer of the cervix..... | 292 |
| 2.4 Cancer of the ovary..... | 293 |
| 2.5 Cancer of the liver..... | 295 |
| 2.6 Cancer of the skin..... | 296 |
| 2.7 Cancer of the colorectum..... | 296 |
| 2.8 Cancer of the thyroid..... | 297 |
| 2.9 Lymphomas..... | 297 |
| 2.10 Cancers of the central nervous system..... | 298 |
| 2.11 Cancer of the urinary tract..... | 298 |
| 2.12 Cancer of the lung..... | 299 |
| 2.13 Cancer of the pancreas..... | 299 |
| 2.14 Cancer of the gallbladder..... | 299 |
| 2.15 Cancer of the stomach..... | 299 |

| | |
|---|------------|
| 2.16 Other cancers | 299 |
| 2.17 Synthesis | 300 |
| 3. Cancer in Experimental Animals | 300 |
| 3.1 Estrogen–progestogen combinations | 300 |
| 3.2 Estrogens | 302 |
| 3.3 Progestogens | 303 |
| 3.4 Synthesis | 304 |
| 4. Other Relevant Data | 305 |
| 4.1 Absorption, distribution, metabolism, and excretion | 305 |
| 4.2 Genetic and related effects | 305 |
| 4.3 Synthesis | 310 |
| 5. Evaluation | 311 |
| References | 311 |
| AZATHIOPRINE | 319 |
| 1. Exposure Data | 319 |
| 1.1 Identification of the agent | 319 |
| 1.2 Use of the agent | 319 |
| 2. Cancer in Humans | 320 |
| 2.1 Transplant recipients | 320 |
| 2.2 Autoimmune disorders | 320 |
| 3. Cancer in Experimental Animals | 321 |
| 4. Other Relevant Data | 325 |
| 4.1 Absorption, distribution, metabolism, and excretion | 325 |
| 4.2 Genotoxic effects | 327 |
| 4.3 Mechanisms of carcinogenesis in organ-transplant patients | 328 |
| 4.4 Synthesis | 328 |
| 5. Evaluation | 329 |
| References | 329 |
| CHLORNAPHAZINE | 333 |
| 1. Exposure Data | 333 |
| 1.1 Identification of the agent | 333 |
| 1.2 Use of the agent | 333 |
| 2. Cancer in Humans | 334 |
| 3. Cancer in Experimental Animals | 334 |
| 4. Other Relevant Data | 334 |
| 5. Evaluation | 335 |
| References | 335 |
| CICLOSPORIN | 337 |
| 1. Exposure Data | 337 |
| 1.1 Identification of the agent | 337 |
| 1.2 Use of the agent | 337 |
| 2. Cancer in Humans | 339 |
| 3. Cancer in Experimental Animals | 340 |

| | |
|--|------------|
| 4. Other Relevant Data | 341 |
| 4.1 Absorption, distribution, metabolism, and excretion..... | 341 |
| 4.2 Cytogenetic effects..... | 341 |
| 4.3 Mechanisms of carcinogenesis | 341 |
| 4.4 Synthesis..... | 343 |
| 5. Evaluation | 343 |
| References | 343 |
| PLANTS CONTAINING ARISTOLOCHIC ACID | 347 |
| 1. Exposure Data | 347 |
| 1.1 Identification of the agent..... | 347 |
| 1.2 Use of the agent | 348 |
| 2. Cancer in Humans..... | 352 |
| 2.1 Case reports | 352 |
| 2.2 Aristolochic acid nephropathy..... | 352 |
| 3. Cancer in Experimental Animals | 352 |
| 3.1 Aristolochic acid | 352 |
| 3.2 Extracts from Aristolochia species..... | 357 |
| 3.3 Herbal remedy containing aristolochic acids | 358 |
| 4. Other Relevant Data | 358 |
| 4.1 Absorption, distribution, metabolism, and excretion..... | 358 |
| 4.2 Toxic effects | 358 |
| 4.3 Genotoxic effects | 358 |
| 4.4 Synthesis..... | 359 |
| 5. Evaluation | 359 |
| References | 360 |
| METHOXSALEN PLUS ULTRAVIOLET A RADIATION | 363 |
| 1. Exposure Data | 363 |
| 1.1 Identification of the agent..... | 363 |
| 1.2 Use of the agent | 363 |
| 2. Cancer in Humans..... | 364 |
| 2.1 Cohort studies | 364 |
| 3. Cancer in Experimental Animals | 366 |
| 3.1 Methoxsalen and UVA..... | 366 |
| 3.2 Methoxsalen alone | 366 |
| 4. Other Relevant Data | 370 |
| 4.1 Absorption, distribution, metabolism and excretion | 370 |
| 4.2 Mechanisms of carcinogenesis | 371 |
| 4.3 Synthesis..... | 372 |
| 5. Evaluation | 372 |
| References | 373 |
| PHENACETIN | 377 |
| 1. Exposure Data | 377 |
| 1.1 Identification of the agent..... | 377 |

| | |
|--|------------|
| 1.2 Use of the agent | 377 |
| 2. Cancer in Humans..... | 378 |
| 2.1 Case reports | 378 |
| 2.2 Case-control studies..... | 378 |
| 3. Cancer in Experimental Animals | 388 |
| 3.1 Analgesic mixtures containing phenacetin | 388 |
| 4. Other Relevant Data | 394 |
| 4.1 Absorption, distribution, excretion, and metabolism..... | 394 |
| 4.2 Genetic and related effects..... | 394 |
| 5. Evaluation | 395 |
| References | 395 |
| LIST OF ABBREVIATIONS..... | 399 |
| CUMULATIVE CROSS INDEX TO IARC MONOGRAPHS | 403 |

NOTE TO THE READER

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer. The *Monographs* evaluate cancer hazards, despite the historical presence of the word ‘risks’ in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a *Monograph* does not mean that it is not carcinogenic. Similarly, identification of cancer sites with *sufficient evidence* or *limited evidence* in humans should not be viewed as precluding the possibility that an agent may cause cancer at other sites.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Section of IARC Monographs, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the *Monographs* as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Section of IARC Monographs, so that corrections can be reported in future volumes.

